Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

1.

The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.

Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, Gray N, Cohen P, Pedrioli P, Clark K, Alessi DR.

PLoS One. 2012;7(6):e39132. doi: 10.1371/journal.pone.0039132. Epub 2012 Jun 18.

PMID:
22723946
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during Toll-like receptor signaling.

Clark K, Takeuchi O, Akira S, Cohen P.

Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17093-8. doi: 10.1073/pnas.1114194108. Epub 2011 Sep 23.

PMID:
21949249
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.

Dzamko N, Chua G, Ranola M, Rowe DB, Halliday GM.

J Parkinsons Dis. 2013;3(2):145-52. doi: 10.3233/JPD-130174.

PMID:
23938344
[PubMed - indexed for MEDLINE]
4.

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.

Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ.

Biochem J. 2010 Sep 15;430(3):405-13. doi: 10.1042/BJ20100784.

PMID:
20659021
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization.

Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR.

Biochem J. 2010 Sep 15;430(3):393-404. doi: 10.1042/BJ20100483.

PMID:
20642453
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.

Hermanson SB, Carlson CB, Riddle SM, Zhao J, Vogel KW, Nichols RJ, Bi K.

PLoS One. 2012;7(8):e43580. doi: 10.1371/journal.pone.0043580. Epub 2012 Aug 28.

PMID:
22952710
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS.

Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.

PMID:
21378983
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.

Doggett EA, Zhao J, Mork CN, Hu D, Nichols RJ.

J Neurochem. 2012 Jan;120(1):37-45. doi: 10.1111/j.1471-4159.2011.07537.x. Epub 2011 Nov 11.

PMID:
22004453
[PubMed - indexed for MEDLINE]
9.

TBK1-targeted suppression of TRIF-dependent signaling pathway of Toll-like receptors by helenalin.

Shin HJ, Youn HS.

Life Sci. 2013 Nov 19;93(22):847-54. doi: 10.1016/j.lfs.2013.09.004. Epub 2013 Sep 15.

PMID:
24044884
[PubMed - indexed for MEDLINE]
10.

The role of TBK1 and IKKε in the expression and activation of Pellino 1.

Smith H, Liu XY, Dai L, Goh ET, Chan AT, Xi J, Seh CC, Qureshi IA, Lescar J, Ruedl C, Gourlay R, Morton S, Hough J, McIver EG, Cohen P, Cheung PC.

Biochem J. 2011 Mar 15;434(3):537-48. doi: 10.1042/BJ20101421.

PMID:
21204785
[PubMed - indexed for MEDLINE]
Free Article
11.

Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components.

Dobrovolskaia MA, Medvedev AE, Thomas KE, Cuesta N, Toshchakov V, Ren T, Cody MJ, Michalek SM, Rice NR, Vogel SN.

J Immunol. 2003 Jan 1;170(1):508-19.

PMID:
12496438
[PubMed - indexed for MEDLINE]
Free Article
12.

Regulation and function of IKK and IKK-related kinases.

Häcker H, Karin M.

Sci STKE. 2006 Oct 17;2006(357):re13. Review.

PMID:
17047224
[PubMed - indexed for MEDLINE]
13.

Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.

Ito G, Fujimoto T, Kamikawaji S, Kuwahara T, Iwatsubo T.

PLoS One. 2014 May 16;9(5):e97988. doi: 10.1371/journal.pone.0097988. eCollection 2014.

PMID:
24836358
[PubMed - in process]
Free PMC Article
14.

Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology.

Zhao J, Hermanson SB, Carlson CB, Riddle SM, Vogel KW, Bi K, Nichols RJ.

Biochem Soc Trans. 2012 Oct;40(5):1158-62. Review.

PMID:
22988882
[PubMed - indexed for MEDLINE]
15.

14-3-3 proteins are promising LRRK2 interactors.

Rudenko IN, Cookson MR.

Biochem J. 2010 Sep 15;430(3):e5-6. doi: 10.1042/BJ20101200.

PMID:
20795948
[PubMed - indexed for MEDLINE]
Free Article
16.

Novel cross-talk within the IKK family controls innate immunity.

Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, Madwed JB, Hough J, McIver EG, Cohen P.

Biochem J. 2011 Feb 15;434(1):93-104. doi: 10.1042/BJ20101701.

PMID:
21138416
[PubMed - indexed for MEDLINE]
Free Article
17.

Characterization of TAE684 as a potent LRRK2 kinase inhibitor.

Zhang J, Deng X, Choi HG, Alessi DR, Gray NS.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28.

PMID:
22335897
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Endotoxin tolerance dysregulates MyD88- and Toll/IL-1R domain-containing adapter inducing IFN-beta-dependent pathways and increases expression of negative regulators of TLR signaling.

Piao W, Song C, Chen H, Diaz MA, Wahl LM, Fitzgerald KA, Li L, Medvedev AE.

J Leukoc Biol. 2009 Oct;86(4):863-75. doi: 10.1189/jlb.0309189. Epub 2009 Aug 5.

PMID:
19656901
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.

Lobbestael E, Zhao J, Rudenko IN, Beylina A, Gao F, Wetter J, Beullens M, Bollen M, Cookson MR, Baekelandt V, Nichols RJ, Taymans JM.

Biochem J. 2013 Nov 15;456(1):119-28. doi: 10.1042/BJ20121772.

PMID:
23937259
[PubMed - indexed for MEDLINE]
20.

Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex.

Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH.

J Immunol. 2005 Sep 1;175(5):3339-46.

PMID:
16116226
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk